# Molecular Cancer Therapeutics

## Table of Contents

### Highlights

2233  **Selected Articles from This Issue**

### MCT First Disclosures

2235  **Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer**

2298  **Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I**

### Review

2245  **Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer**

2319  **Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors**

### Small Molecule Therapeutics

2256  **The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade**

2267  **An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells**

2278  **Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin**

### Large Molecule Therapeutics

2330  **LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia**

2340  **Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function**
TABLE OF CONTENTS

2353  Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer  

2363  Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)  

2371  Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction  
Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordeheim, Catherine Thieblemont, Denis Sahin, Christian Klein, and Charles Dumontet

2382  Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK  
Daniela Pucciarelli, Steven P. Angus, Benjamin Huang, Chi Zhang, Hiroki J. Nakaoka, Ganesh Krishnamurthi, Sourav Bandyopadhyay, D. Wade Clapp, Kevin Shannon, Gary L. Johnson, and Jean L. Nakamura

2396  Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer  
Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Allá, Sanghoon Lee, Robert L. Coleman, and Anil K. Sood

ABOUT THE COVER

In this issue of Molecular Cancer Therapeutics, Jin and colleagues describe the discovery and mechanism of novel anti-CD73 antibody (Hu001) and CD73-ADC (Hu001-MMAE). High CD73 staining was found in lung cancer epithelial tumor cells and stromal cells in tumor microenvironment, pictured on our cover. The anti-tumor efficacy of Hu001 required both the Fc-dependent cell-mediated cytotoxicity and a multifaceted remodeling in the tumor immune microenvironment. The novel Hu001-MMAE elicited dramatic dual benefits in killing CD73-high tumors while simultaneously promoting the effector function in T lymphocytes and dendritic cells. Read the full article on page 2340.